Johnson & Johnson’s Tremfya Receives the EC’s Approval for Active Ulcerative Colitis (UC)
Shots:
- The EC has approved Tremfya to treat mod. to sev. active UC adults with inadequate response, no response or intolerance to SoCs or biologics; CHMP recommendation under EC review for mod. to sev. active Crohn’s disease with decision anticipated later 2025
- Approval was based on P-IIb/III (QUASAR) trial assessing Tremfya (IV induction: 200mg Q4W; SC maintenance: 100mg at Wk. 16 then Q8W or 200mg at Wk. 12 then Q4W for inadequate response) vs PBO in UC pts
- Study showed that 50% (200mg, SC) & 45% (100mg, SC) vs 19% reached the 1EP of clinical remission with 34% (200mg, SC) & 35% (100mg, SC) vs 15% achieving endoscopic remission at Wk. 44
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Reports P-III (Vivacity-MG3) Trial Data of Nipocalimab for Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
